NGM·Healthcare·$351M·#98 / 520 in Healthcare

EOLS Evolus, Inc. Common Stock

63SOLID

CATEGORY BREAKDOWN

GROWTH19
QUALITY64
STABILITY69
VALUATION99
GOVERNANCE83

METRIC BREAKDOWN

Revenue Growth (YoY)

Year-over-year revenue growth rate

+11.6%
19

> 50% strong

Gross Margin

Revenue retained after direct costs

66.3%
94

> 50% strong

Cash Runway

Months of cash at current burn rate

15 months
54

> 24 months ideal

Debt / Equity

Total debt relative to shareholder equity

-670.8%
100

< 25% strong

Price / Sales

Market cap relative to trailing revenue

1.2x
99

< 3x strong

Rule of 40

Growth rate plus operating margin

-1
19

> 40 excellent

Insider Ownership

Percentage of shares held by insiders

16.4%
78

> 20% strong

Share Dilution (12M)

Share count increase over last 12 months

+0.9%
94

< 5% ideal

5 more metrics available

Unlock all 8 metrics, score history, watchlist, and side-by-side comparison.

Try Free for 30 Days

AI ANALYSIS REPORT

AI-GENERATED

BUSINESS SUMMARY

Evolus, Inc. Common Stock (EOLS) is a healthcare company trading on NGM with a market capitalization of $351M. The company currently carries a SOLID rating of 63/100, indicating above-average fundamental quality. The fundamental profile shows moderate revenue growth at 11.6% year-over-year, paired with strong gross margins well above industry average at 66.3%. The balance sheet shows a net cash position (negative debt-to-equity), meaning more cash than debt, and the company has moderate cash runway of about 1 year.

VERDICT

EOLS scores 63/100 — a solid fundamental profile with room for improvement in select areas. This report is based on the latest available financial data and is intended as a starting point for research, not a buy or sell recommendation.

MARKET OPPORTUNITY

In the healthcare sector, cash runway and pipeline progress are critical metrics. Revenue quality depends on whether income comes from product sales, partnerships, or milestones. Evolus, Inc. Common Stock operates with meaningful insider ownership of 16.4%, which provides a signal about management's confidence in the company's direction. At a market cap of $351M, the company is attractively valued at under 3x price-to-sales at 1.2x P/S. The combination of these factors positions EOLS as a potentially interesting opportunity for investors seeking fundamental quality in the small-cap space.

REVENUE QUALITY

Revenue growth stands at 11.6% year-over-year, which is in line with the typical small-cap growth rate. Gross margins of 66.3% are strong and suggest pricing power or an asset-light business model. The Rule of 40 score of -1 is well below the benchmark, indicating challenges in both growth and profitability. Cash runway of 15 months is adequate but should be monitored.

COMPETITIVE ADVANTAGE

Evaluating Evolus, Inc. Common Stock's competitive position requires looking beyond the numbers. Insider ownership at 16.4% is relatively low, which may indicate that management's interests are less aligned with shareholders. The high gross margins suggest some form of competitive moat — whether through proprietary technology, brand value, regulatory barriers, or network effects. Share count management has been reasonable. Investors should research the specific sources of competitive advantage — patents, customer switching costs, scale economies, or brand — that could protect margins over time.

GROWTH THESIS

EOLS presents a reasonable fundamental case at current levels. The low 1.2x P/S ratio could represent value if the company can stabilize or accelerate its growth. Key catalysts to watch include: revenue growth trajectory over the next 2-3 quarters, margin expansion or contraction, and any changes in insider buying or selling activity.

KEY RISKS

Execution risk is significant — many small-cap companies in this sector fail to transition from growth to profitability. Limited cash runway of 15 months means the company may need to raise capital, potentially diluting existing shareholders. Small-cap stocks carry inherently higher risk than large-caps, including limited analyst coverage, lower institutional ownership, and higher sensitivity to market downturns. Always conduct thorough due diligence beyond quantitative metrics.

Full AI Report available

Unlock the complete analysis including market opportunity, revenue quality, competitive moat, growth thesis, and risk assessment.

Try Free for 30 Days

Report generated: Mar 26, 2026

SCORE HISTORY

Track how this score changes over time. Start your free trial to see the full score trend chart.

SCORE ALERT

Get notified when EOLS's score changes by 5+ points.

DATA INFO

Last updated: Mar 11, 2026

Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.